Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
McKesson
AstraZeneca
Covington
QuintilesIMS
Colorcon
Julphar
Fish and Richardson
Citi
Cerilliant

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,211,600

« Back to Dashboard

Which drugs does patent 7,211,600 protect, and when does it expire?

Patent 7,211,600 protects SUTENT and is included in one NDA.

This patent has thirteen patent family members in thirteen countries.
Summary for Patent: 7,211,600
Title:Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
Abstract:The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
Inventor(s): Lipson; Ken (San Mateo, CA), McMahon; Gerald (Kenwood, CA)
Assignee: Sugen Inc. (South San Francisco, CA)
Application Number:11/205,474
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 7,211,600

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-001 Jan 26, 2006 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB ➤ Subscribe
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-002 Jan 26, 2006 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB ➤ Subscribe
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-004 Mar 31, 2009 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB ➤ Subscribe
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-003 Jan 26, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,211,600

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2395461 ➤ Subscribe
Germany 60029138 ➤ Subscribe
Denmark 1255536 ➤ Subscribe
European Patent Office 1255536 ➤ Subscribe
Spain 2267605 ➤ Subscribe
Hong Kong 1050642 ➤ Subscribe
Japan 2004500363 ➤ Subscribe
Japan 5004392 ➤ Subscribe
Mexico PA02006263 ➤ Subscribe
New Zealand 519697 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Fish and Richardson
McKinsey
Novartis
Baxter
UBS
Healthtrust
Merck
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot